References
Scott LJ, Lamb HM: Rofecoxib. Drugs 58:499-505, 1999
Huster D, Schubert C, Berr F, Mossner J, Caca K: Rofecoxib-induced cholestatic hepatitis: treatment with molecular adsorbent recycling system (MARS). J Hepatol 3:413-414, 2002
Maddrey WC, Maurath CJ, Verbung KM, Geiss GS: The hepatic safety and tolerability of the novel cyclooxygenase-2 inhibitor celecoxib. Am J Ther 7:153-158, 2000
Galan MV, Gordon SC, Silverman AL: Celecoxib-induced cholestatic hepatitis. Ann Intern Med 134:254, 2001
O'Beirne JP, Cairns SR. Drug points: cholestatic hepatitis in association with celecoxib. BMJ 323:23, 2001
Alegria P, Lebre L, Chagas C: Celecoxib-induced cholestatic hepatotoxicity in a patient with cirrhosis. Ann Intern Med 137:75, 2002
Grieco A, Miele L, Giorgi A, Civello IM, Gasbarrini G: Acute cholestatic hepatitis associated with celecoxib. Ann Pharmacother 36:1887-1889, 2002
Carillo-Jimenez R, Nurnberger M: Celecoxib-induced acute pancreatits and hepatitis: a case report. Arch Intern Med 160:553-554, 2000
Nachimuthu S, Volfinzon L, Gopal L: Acute hepatocellular and cholestatic injury in a patient taking celecoxib. Postgrad Med J 77:548-550, 2001
Kaplowitz N: Drug-induced liver disorders: Implications for drug development and regulation. Drug Safety 24:483-490, 2001
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Papachristou, G.I., Demetris, A.J. & Rabinovitz, M. CASE REPORT: Acute Cholestatic Hepatitis Associated with Long-Term Use of Rofecoxib. Dig Dis Sci 49, 459–461 (2004). https://doi.org/10.1023/B:DDAS.0000020503.92146.8b
Issue Date:
DOI: https://doi.org/10.1023/B:DDAS.0000020503.92146.8b